SC-60

SC-60 is a derivative of Sorafenib. SC-60 exerts its anti-tumor effect by activating the phosphatase activity of SHP-1, thereby inhibiting the STAT3 signaling pathway. SC-60 exhibits strong proliferation inhibitory activity in various hepatocellular carcinoma (HCC) cell lines. SC-60 downregulates the expression of downstream anti-apoptotic proteins (such as Bcl-2, Cyclin D1, Survivin), ultimately inducing caspase-dependent apoptosis. SC-60 significantly inhibits tumor growth in xenograft tumor models. SC-60 can be used for the study of HCC[1].

1421677-31-7

12352005

Apoptosis; Bcl-2 Family; Caspase; CDK; Drug Derivative; SHP1; STAT; Survivin

Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Cancer-Kinase/protease

Cancer

N#CC1=CC=C(C=C1)OC2=CC(NC(NC3=CC=C(C)C(OC4=CC=C(C=C4)C#N)=C3)=O)=CC=C2C

C29H22N4O3

474.51

[1]Tai WT, et al. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model. Mol Cancer Ther. 2014 Jan;13 (1) :27-36.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W717425/

Reference compound1

No Development Reported

Bcl-2; STAT3